Plans to expand African vaccine production face steep hurdles
In March 2022, when the pandemic was still raging, the messenger RNA (mRNA) company Moderna announced it would build a $500 million plant in Kenya to manufacture half a billion doses of its COVID-19 vaccine annually. “
This is major
,” Kenyan President William Ruto said at the time. The plant would help reduce Africa’s dependence on vaccines produced elsewhere, Ruto said—a situation that had turned disastrous during the pandemic—and bring economic benefits as well.
But Moderna may never break ground on the Kenya factory. On 11 April, the company said it had
“paused its efforts”
becau...
Source: Science of Aging Knowledge Environment - April 16, 2024 Category: Geriatrics Source Type: research
Recent advances in immunotherapies against infectious diseases
Immunother Adv. 2020 Nov 25;1(1):ltaa007. doi: 10.1093/immadv/ltaa007. eCollection 2021 Jan.ABSTRACTImmunotherapies are disease management strategies that target or manipulate components of the immune system. Infectious diseases pose a significant threat to human health as evidenced by countries continuing to grapple with several emerging and re-emerging diseases, the most recent global health threat being the SARS-CoV2 pandemic. As such, various immunotherapeutic approaches are increasingly being investigated as alternative therapies for infectious diseases, resulting in significant advances towards the uncovering of path...
Source: Cancer Control - April 16, 2024 Category: Cancer & Oncology Authors: Dharanidharan Ramamurthy Trishana Nundalall Sanele Cingo Neelakshi Mungra Maryam Karaan Krupa Naran Stefan Barth Source Type: research
A targetable receptor-binding site on PfCyRPA to aid in the fight against malaria
Trends Parasitol. 2024 Apr 10:S1471-4922(24)00083-7. doi: 10.1016/j.pt.2024.04.001. Online ahead of print.ABSTRACTRecently, Day et al. identified a receptor-binding site on the malaria parasite protein PfCyRPA that binds the host sugar Neu5Ac, and they found that disrupting this interaction impedes parasite growth. A map of the receptor-binding site identifies an attractive target for antimalarial vaccines and therapeutics.PMID:38604871 | DOI:10.1016/j.pt.2024.04.001 (Source: Trends in Parasitology)
Source: Trends in Parasitology - April 11, 2024 Category: Parasitology Authors: Thayne H Dickey Niraj H Tolia Source Type: research
A systematic review on malaria and dengue vaccines for the effective management of these mosquito borne diseases: Improving public health
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - April 11, 2024 Category: Allergy & Immunology Authors: Hind M. Al-OsaimiMohammed KananLujain MarghlaniBadria Al-RowailiReem AlbalawiAbrar SaadSaba AlasmariKhaled AlthobaitiZainab AlhulailiAbeer AlanziRawan AlqarniRazan AlsofiyaniReem Shrwania Department of Pharmacy Services Administration, King Fahad Medical Source Type: research
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-na ïve adults
CONCLUSION: Co-administration of RTS,S and FMP1/AS02 reduced anti-RTS,S antibody, but did not affect tolerability, cellular immunity, or efficacy in a stringent CHMI model. Absence of efficacy or delay of patency in the sporozoite challenge model in the FMP1/AS02 group did not rule out efficacy of FMP1/AS02 in an endemic population. However, a Phase IIb trial of FMP1/AS02 in children in malaria-endemic Kenya did not demonstrate efficacy against natural infection.CLINICALTRIALS: gov identifier: NCT01556945.PMID:38584058 | DOI:10.1016/j.vaccine.2024.03.072 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: J F Cummings M E Polhemus K E Kester C F Ockenhouse R A Gasser P Coyne G Wortmann R K Nielsen K Schaecher C A Holland U Krzych N Tornieporth L A Soisson E Angov D G Heppner RTS,S Vaccine Evaluation Group Source Type: research
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-na ïve adults
CONCLUSION: Co-administration of RTS,S and FMP1/AS02 reduced anti-RTS,S antibody, but did not affect tolerability, cellular immunity, or efficacy in a stringent CHMI model. Absence of efficacy or delay of patency in the sporozoite challenge model in the FMP1/AS02 group did not rule out efficacy of FMP1/AS02 in an endemic population. However, a Phase IIb trial of FMP1/AS02 in children in malaria-endemic Kenya did not demonstrate efficacy against natural infection.CLINICALTRIALS: gov identifier: NCT01556945.PMID:38584058 | DOI:10.1016/j.vaccine.2024.03.072 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: J F Cummings M E Polhemus K E Kester C F Ockenhouse R A Gasser P Coyne G Wortmann R K Nielsen K Schaecher C A Holland U Krzych N Tornieporth L A Soisson E Angov D G Heppner RTS,S Vaccine Evaluation Group Source Type: research
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-na ïve adults
CONCLUSION: Co-administration of RTS,S and FMP1/AS02 reduced anti-RTS,S antibody, but did not affect tolerability, cellular immunity, or efficacy in a stringent CHMI model. Absence of efficacy or delay of patency in the sporozoite challenge model in the FMP1/AS02 group did not rule out efficacy of FMP1/AS02 in an endemic population. However, a Phase IIb trial of FMP1/AS02 in children in malaria-endemic Kenya did not demonstrate efficacy against natural infection.CLINICALTRIALS: gov identifier: NCT01556945.PMID:38584058 | DOI:10.1016/j.vaccine.2024.03.072 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: J F Cummings M E Polhemus K E Kester C F Ockenhouse R A Gasser P Coyne G Wortmann R K Nielsen K Schaecher C A Holland U Krzych N Tornieporth L A Soisson E Angov D G Heppner RTS,S Vaccine Evaluation Group Source Type: research
A paradigm for Africa-centric vaccine development in Equatorial Guinea
Trends Parasitol. 2024 Apr 5:S1471-4922(24)00072-2. doi: 10.1016/j.pt.2024.03.005. Online ahead of print.ABSTRACTThe Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development of vaccines in Africa, for Africa. We review achievements and challenges of this pioneering, award-winning, public-private partnership which offers a model for future Africa-centric clinical research and development (R&D).PMID:38582683 | DOI:10.1016/j.pt.2024.03.005 (Source: Trends in Parasitology)
Source: Trends in Parasitology - April 6, 2024 Category: Parasitology Authors: Peter F Billingsley Thomas L Richie Salim Abdulla Mitoha Ondo'o Ayekaba Claudia A Daubenberger Gu íllermo A Garcia Stephen L Hoffman Source Type: research
A paradigm for Africa-centric vaccine development in Equatorial Guinea
Trends Parasitol. 2024 Apr 5:S1471-4922(24)00072-2. doi: 10.1016/j.pt.2024.03.005. Online ahead of print.ABSTRACTThe Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development of vaccines in Africa, for Africa. We review achievements and challenges of this pioneering, award-winning, public-private partnership which offers a model for future Africa-centric clinical research and development (R&D).PMID:38582683 | DOI:10.1016/j.pt.2024.03.005 (Source: Trends in Parasitology)
Source: Trends in Parasitology - April 6, 2024 Category: Parasitology Authors: Peter F Billingsley Thomas L Richie Salim Abdulla Mitoha Ondo'o Ayekaba Claudia A Daubenberger Gu íllermo A Garcia Stephen L Hoffman Source Type: research
A paradigm for Africa-centric vaccine development in Equatorial Guinea
Trends Parasitol. 2024 Apr 5:S1471-4922(24)00072-2. doi: 10.1016/j.pt.2024.03.005. Online ahead of print.ABSTRACTThe Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development of vaccines in Africa, for Africa. We review achievements and challenges of this pioneering, award-winning, public-private partnership which offers a model for future Africa-centric clinical research and development (R&D).PMID:38582683 | DOI:10.1016/j.pt.2024.03.005 (Source: Trends in Parasitology)
Source: Trends in Parasitology - April 6, 2024 Category: Parasitology Authors: Peter F Billingsley Thomas L Richie Salim Abdulla Mitoha Ondo'o Ayekaba Claudia A Daubenberger Gu íllermo A Garcia Stephen L Hoffman Source Type: research
A paradigm for Africa-centric vaccine development in Equatorial Guinea
Trends Parasitol. 2024 Apr 5:S1471-4922(24)00072-2. doi: 10.1016/j.pt.2024.03.005. Online ahead of print.ABSTRACTThe Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development of vaccines in Africa, for Africa. We review achievements and challenges of this pioneering, award-winning, public-private partnership which offers a model for future Africa-centric clinical research and development (R&D).PMID:38582683 | DOI:10.1016/j.pt.2024.03.005 (Source: Trends in Parasitology)
Source: Trends in Parasitology - April 6, 2024 Category: Parasitology Authors: Peter F Billingsley Thomas L Richie Salim Abdulla Mitoha Ondo'o Ayekaba Claudia A Daubenberger Gu íllermo A Garcia Stephen L Hoffman Source Type: research
A paradigm for Africa-centric vaccine development in Equatorial Guinea
Trends Parasitol. 2024 Apr 5:S1471-4922(24)00072-2. doi: 10.1016/j.pt.2024.03.005. Online ahead of print.ABSTRACTThe Equatorial Guinea Malaria Vaccine Initiative (EGMVI) highlights how long-term African government and international energy industry investment, plus novel partnerships, can enable clinical development of vaccines in Africa, for Africa. We review achievements and challenges of this pioneering, award-winning, public-private partnership which offers a model for future Africa-centric clinical research and development (R&D).PMID:38582683 | DOI:10.1016/j.pt.2024.03.005 (Source: Trends in Parasitology)
Source: Trends in Parasitology - April 6, 2024 Category: Parasitology Authors: Peter F Billingsley Thomas L Richie Salim Abdulla Mitoha Ondo'o Ayekaba Claudia A Daubenberger Gu íllermo A Garcia Stephen L Hoffman Source Type: research
Malaria Therapeutic Paradigm: An Evolution Towards Commercial Drug Delivery Technology
In this study, we are going to discuss about the seminal delivery systems for drug which are in lab, market, and clinical trials for treatment of malaria. Also, we focused on the commercial and conventional drug delivery systems which can be more effective and the challenges behind their success. (Source: Current Treatment Options in Infectious Diseases)
Source: Current Treatment Options in Infectious Diseases - April 5, 2024 Category: Infectious Diseases Source Type: research
YF17D-based vaccines - standing on the shoulders of a giant
Eur J Immunol. 2024 Apr 3:e2250133. doi: 10.1002/eji.202250133. Online ahead of print.ABSTRACTLive-attenuated yellow fever vaccine (YF17D) was developed in the 1930s as the first ever empirically derived human vaccine. Ninety years later, it is still a benchmark for vaccines made today. YF17D triggers a particularly broad and polyfunctional response engaging multiple arms of innate, humoral and cellular immunity. This unique immunogenicity translates into an extraordinary vaccine efficacy and outstanding longevity of protection, possibly by single-dose immunization. More recently, progress in molecular virology and synthet...
Source: European Journal of Immunology - April 4, 2024 Category: Allergy & Immunology Authors: Lorena Sanchez-Felipe Yeranddy A Alpizar Ji Ma Lotte Coelmont Kai Dallmeier Source Type: research
Extracellular vesicles derived from plasmodium-infected red blood cells alleviate cerebral malaria in plasmodium berghei ANKA-infected C57BL/6J mice
This study extracted EVs from BALB/c mice infected with Plasmodium yoelii 17XNL (P.y17XNL). C57BL/6J mice were intravenously immunized with EVs (EV-I.V. + CM group) or subcutaneously vaccinated with the combination of EVs and CpG ODN-1826 (EV + CPG ODN-S.C. + CM group) on days 0 and 20, followed by infection with Plasmodium berghei ANKA (P.bANKA) on day 20 post-second immunization. We monitored Parasitemia and survival rate. The integrity of the Blood-brain barrier (BBB) was examined using Evans blue staining.The levels of cytokines and adhesion molecules were evaluated using Luminex, RT-qPCR, and WB. Brain pathology was e...
Source: International Immunopharmacology - April 3, 2024 Category: Allergy & Immunology Authors: Yinyi Lv Shuang Wu Qing Nie Shuangchun Liu Wenxin Xu Guang Chen Yunting Du Jinguang Chen Source Type: research
